Curr Opin Pulm Med. 2018 Sep;24(5):425-431. doi: 10.1097/MCP.0000000000000512.
Historically, because of the necessity of parenteral anticoagulation, patients with acute pulmonary embolism are hospitalized until stable oral anticoagulation is achieved. Despite improvements in prognostic risk stratification and the introduction of the direct oral anticoagulants, home treatment is still not widely applied. Main advantages of home treatment involve improvement of quality of life and significant healthcare cost reduction. In this review, we summarized recent published data on home treatment of patients with acute pulmonary embolism.
Although a significant decrease in mean duration of hospital admission for pulmonary embolism has been demonstrated over the last decade in Europe, most pulmonary embolism patients are currently hospitalized while they might be treated in an outpatient setting. In recent years, five major studies have been performed, in which the decision to initiate home treatment was based on the Hestia criteria in most patients. Over 98% of patients treated at home had an uncomplicated course.
Home treatment of acute pulmonary embolism is suggested to be feasible and safe in 30-55% of all patients. Results of ongoing trials will provide more insight in the optimal strategy to select patients with pulmonary embolism who are eligible for home treatment and likely will result in more widespread application of this practice.
从历史上看,由于需要进行肠外抗凝治疗,急性肺栓塞患者需要住院直至稳定口服抗凝治疗。尽管预后风险分层得到了改善,并且直接口服抗凝剂也已问世,但居家治疗仍未广泛应用。居家治疗的主要优势在于提高生活质量和显著降低医疗保健成本。在本次综述中,我们总结了最近发表的关于急性肺栓塞患者居家治疗的相关数据。
尽管过去十年中,欧洲急性肺栓塞患者的平均住院时间已显著缩短,但目前大多数肺栓塞患者仍住院治疗,而实际上他们可能可以在门诊接受治疗。近年来,已开展了五项大型研究,其中大多数患者都是基于 Hestia 标准来决定是否开始居家治疗。超过 98%的居家治疗患者病情平稳。
在 30%-55%的所有患者中,急性肺栓塞的居家治疗是可行且安全的。正在进行的试验结果将更深入地了解选择适合居家治疗的肺栓塞患者的最佳策略,并可能使这种治疗方法得到更广泛的应用。